Papers by Diego Sepulveda-falla

Journal of Clinical Investigation, 2014
onset. Mutations in the gene encoding presenilin-1 (PS1) are found in approximately 80% of cases ... more onset. Mutations in the gene encoding presenilin-1 (PS1) are found in approximately 80% of cases of FAD, with some of these patients presenting cerebellar damage with amyloid plaques and ataxia with unclear pathophysiology. A Colombian kindred carrying the PS1-E280A mutation is the largest known cohort of PS1-FAD patients. Here, we investigated PS1-E280A-associated cerebellar dysfunction and found that it occurs early in PS1-E208A carriers, while cerebellar signs are highly prevalent in patients with dementia. Postmortem analysis of cerebella of PS1-E280A carrier revealed greater Purkinje cell (PC) loss and more abnormal mitochondria compared with controls. In PS1-E280A tissue, ER/mitochondria tethering was impaired, Ca 2+ channels IP3Rs and CACNA1A were downregulated, and Ca 2+ -dependent mitochondrial transport proteins MIRO1 and KIF5C were reduced. Accordingly, expression of PS1-E280A in a neuronal cell line altered ER/ mitochondria tethering and transport compared with that in cells expressing wild-type PS1. In a murine model of PS1-FAD, animals exhibited mild ataxia and reduced PC simple spike activity prior to cerebellar β-amyloid deposition. Our data suggest that impaired calcium homeostasis and mitochondrial dysfunction in PS1-FAD PCs reduces their activity and contributes to motor coordination deficits prior to Aβ aggregation and dementia. We propose that PS1-E280A affects both Ca 2+ homeostasis and Aβ precursor processing, leading to FAD and neurodegeneration. Familial Alzheimer's disease (FAD) is a rare variant of Alzheimer's disease (AD), the most common form of dementia, which is characterized by early onset (<65 years old), increased severity, and autosomal dominant inheritance of mutations in amyloid precursor protein (APP), presenilin-1 (PS1), and PS2 (1). PS1 mutations, of which around 180 have been described, account for 80% of all FAD cases (2). There is wide clinical variability in PS1-FAD, including epileptic seizures and cerebellar ataxia. At the neuropathological level, brain tissue of PS1-FAD patients shows characteristic β-amyloid (Aβ) plaque morphology and localized damage such as cerebellar degeneration (3, 4). An interesting FAD mutation is PS1-E280A (E280A-FAD), which is present in a large kindred in Colombia with more than 5,000 members and around 600 affected individuals. Apart from common FAD symptoms, such as epilepsy and ataxia, E280A-FAD patients show typical clinical endophenotypes, including aphasia and variable age of onset (5). PS1 provides the catalytic core of the γ-secretase complex, which is involved in amyloidogenic processing of APP, which defines the length of the Aβ peptide (6, 7). PS1 mutations can increase the ratio of longer Aβ peptides, which are more prone to aggregation and show higher neurotoxicity (8). On the other hand, independent from its role in the γ-secretase complex, PS1 may contribute to several other functions, including protein turnover (9), autophagy (10), and ER Ca 2+ regulation (11). Up to which point these functions participate in the pathogenesis of FAD remains to be elucidated.

Brain Pathology, 2011
Early-onset familial Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;am... more Early-onset familial Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease (AD) caused by presenilin-1 mutation E280A (PS1-E280A) presents wide clinical and neuropathological variabilities. We characterized clinically and neuropathologically PS1-E280A focusing in cerebellar involvement and compared it with early-onset sporadic Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease (EOSAD). Twelve E280A brains and 12 matched EOSAD brains were analyzed for beta-amyloid and hyperphosphorylated tau (pTau) morphology, beta-amyloid subspecies 1-40, 1-42 levels, pTau levels, and expression of stress kinases in frontal cortex and cerebellum. The data were correlated to clinical and genetic findings. We observed higher beta-amyloid load, beta-amyloid 1-42 and pTau concentrations in frontal cortex of PS1-E280A compared with EOSAD. High beta-amyloid load was found in the cerebellum of PS1-E280A and EOSAD patients. In PS1-E280A, beta-amyloid localized to the molecular and Purkinje cell layers, whereas EOSAD showed them in Purkinje and granular cell layers. Surprisingly, 11 out of 12 PS1-E280A patients showed deposition of pTau in the cerebellum. Also, seven out of 12 PS1-E280A patients presented cerebellar ataxia. We conclude that deposition of beta-amyloid in the cerebellum is prominent in early-onset AD irrespective of genetic or sporadic origin. The presence of pTau in cerebellum in PS1-E280A underscores the relevance of cerebellar involvement in AD and might be correlated to clinical phenotype.

The Lancet Neurology, 2011
Mild cognitive impairment (MCI) and pre-MCI have been proposed as stages preceding Alzheimer&... more Mild cognitive impairment (MCI) and pre-MCI have been proposed as stages preceding Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease (AD) dementia. We assessed descendants of individuals with a mutation in presenilin 1 (PSEN1) that causes familial AD, with the aim of identifying distinct stages of clinical progression to AD dementia. We retrospectively studied a cohort of descendants of carriers of the PSEN1 E280A mutation. Pre-dementia cognitive impairment was defined by a score 2 SD away from normal values in objective cognitive tests, and was subdivided as follows: asymptomatic pre-MCI was defined by an absence of memory complaints and no effect on activities of daily living; symptomatic pre-MCI was defined by a score on the subjective memory complaints checklist higher than the mean and no effect on activities of daily living; and MCI was defined by a score on the subjective memory complaints checklist higher than the mean, with no effect on basic activities of daily living and little or no effect on complex daily activities. Dementia was defined according to the diagnostic and statistical manual of mental disorders, fourth edition. Reference mean scores were those of participants who did not carry the PSEN1 E280A mutation. We used the Turnbull survival analysis method to identify ages at onset of each stage of the disease. We measured the time from birth until onset of the three pre-dementia stages, dementia, and death, and assessed decline in cognitive domains for each stage. Follow-up was from Jan 1, 1995, to Jan 27, 2010. 1784 patients were initially identified, 449 of whom were PSEN1 E280A carriers who had complete clinical follow-up. Median age at onset was 35 years (95% CI 30-36) for asymptomatic pre-MCI, 38 years (37-40) for symptomatic pre-MCI, 44 years (43-45) for MCI, and 49 years (49-50) for dementia. The median age at death was 59 years (95% CI 58-61). The median time of progression from asymptomatic to symptomatic pre-MCI was 4 years (95% CI 2-8), from symptomatic pre-MCI to MCI was 6 years (4-7), from MCI to dementia was 5 years (4-6), and from dementia to death was 10 years (9-12). The cognitive profile was predominantly amnestic and was associated with multiple domains. Affected domains showed variability in initial stages, with some transient recovery in symptomatic pre-MCI followed by continuous decline. Clinical deterioration can be detected as measurable cognitive impairment around two decades before dementia onset in PSEN1 E280A carriers. Onset and progression of pre-dementia stages should be considered in the investigation and use of therapeutic interventions for familial AD. Departamento Administrativo de Ciencia, Tecnología e Innovación, COLCIENCIAS, Republic of Colombia.

Journal of Alzheimer's Disease, 2012
Presenilin 1 (PS1) mutations are the most common cause of early-onset familial Alzheimer's diseas... more Presenilin 1 (PS1) mutations are the most common cause of early-onset familial Alzheimer's disease (EOFAD). They show a common phenotypic profile characterized by early age of onset, severe dementia and distinct neurodegeneration. The largest population of EOFAD carries the E280A mutation in PS1 and resides in Antioquia, Colombia, currently comprising around 5,000 individuals. Carriers start showing memory impairment in the third decade of life, followed by progressive impairment of language and other cognitive processes. They reach mild cognitive impairment around 45 and dementia around 50 years of age. There is some phenotypic variability among the carriers of this single PS1 mutation. Some patients present with epilepsy, verbal impairment, and cerebellar ataxia. Neuropathologically, PS1 E280A cases show pronounced brain atrophy, severe amyloid- pathology, distinct hyperphosphorylated tau-related pathology, and cerebellar damage. The earliest event identified by functional magnetic imaging resonance is hyperactivation within the right anterior hippocampus around 33 years of age. This well-studied population with a clear pre-clinical profile and wide phenotypic variability in age of onset and clinical presentation is ideally suited for clinical trials and to study molecular mechanisms of Alzheimer's disease.

Brain, 2014
Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease is the most c... more Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease is the most common form of dementia and the generation of oligomeric species of amyloid-β is causal to the initiation and progression of it. Amyloid-β oligomers bind to the N-terminus of plasma membrane-bound cellular prion protein (PrP(C)) initiating a series of events leading to synaptic degeneration. Composition of bound amyloid-β oligomers, binding regions within PrP(C), binding affinities and modifiers of this interaction have been almost exclusively studied in cell culture or murine models of Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease and our knowledge on PrP(C)-amyloid-β interaction in patients with Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease is limited regarding occurrence, binding regions in PrP(C), and size of bound amyloid-β oligomers. Here we employed a PrP(C)-amyloid-β binding assay and size exclusion chromatography on neuropathologically characterized Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease and non-demented control brains (n = 15, seven female, eight male, average age: 79.2 years for Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease and n = 10, three female, seven male, average age: 66.4 years for controls) to investigate amyloid-β-PrP(C) interaction. PrP(C)-amyloid-β binding always occurred in Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease brains and was never detected in non-demented controls. Neither expression level of PrP(C) nor known genetic modifiers of Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease, such as the PrP(C) codon 129 polymorphism, influenced this interaction. In Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease brains, binding of amyloid-β to PrP(C) occurred via the PrP(C) N-terminus. For synthetic amyloid-β42, small oligomeric species showed prominent binding to PrP(C), whereas in Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease brains larger protein assemblies containing amyloid-β42 bound efficiently to PrP(C). These data confirm Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease specificity of binding of amyloid-β to PrP(C) via its N-terminus in a large cohort of Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease/control brains. Differences in sizes of separated protein fractions between synthetic and brain-derived amyloid-β binding to PrP(C) suggest that larger assemblies of amyloid-β or additional non-amyloid-β components may play a role in binding of amyloid-β42 to PrP(C) in Alzheimer&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s disease.
Neurology, 2002
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADAS... more Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is caused by mutations in the notch3 epidermal growth factor-like repeats. A Colombian kindred carries a novel C455R mutation located in the predicted ligand-binding domain. Stroke occurred in the patients at an unusually early age (median age: 31 years) in comparison to the more frequent onset in the fourth decade of life in other CADASIL populations, including a second Colombian kindred with an R1031C mutation.

Primary angiitis of the central nervous system (PACNS) is a rare but serious condition. A fractio... more Primary angiitis of the central nervous system (PACNS) is a rare but serious condition. A fraction of patients suffering from PACNS concurrently exhibit pronounced cerebral amyloid angiopathy (CAA) which is characterized by deposits of amyloid-β (Aβ) in and around the walls of small and medium-sized arteries of the brain. PACNS with CAA has been identified as a distinct disease entity, termed Aβ-related angiitis (ABRA). Evidence points to an immune reaction to vessel wall Aβ as the trigger of vasculitis. To investigate whether the inflammatory response to Aβ has (1) any effect on the status of immune activation in the brain parenchyma and (2) leads to clearance of Aβ from brain parenchyma. We studied immune activation and Aβ load by quantitative immunohistochemical analysis in brain parenchyma adjacent to affected vessels in 11 ABRA patients and 10 matched CAA controls. ABRA patients showed significantly increased immune activation and decreased Aβ loads in the brain parenchyma adjacent to affected vessels. Our results are in line with the hypothesis of ABRA being the result of an excessive immune response to Aβ and show that this can lead to enhanced clearance of Aβ from the brain parenchyma by immune-mediated mechanisms.

Acta Neuropathologica, 2013
Precursor Protein (APP) or Presenilin (PSEN) genes. Studies from families with ADAD have been cri... more Precursor Protein (APP) or Presenilin (PSEN) genes. Studies from families with ADAD have been critical to support the amyloid cascade hypothesis of Alzheimer disease (AD), the basis for the current development of amyloid-based disease-modifying therapies in sporadic AD (SAD). However, whether the pathological changes in APP processing in the CNS in ADAD are similar to those observed in SAD remains unclear. In this study, we measured b-site APP-cleaving enzyme (BACE) protein levels and activity, APP and APP C-terminal fragments in brain samples from subjects with ADAD carrying APP or PSEN1 mutations (n = 18), patients with SAD (n = 27) and agematched controls (n = 22). We also measured sAPPb and BACE protein levels, as well as BACE activity, in CSF from individuals carrying PSEN1 mutations (10 mutation carriers and 7 non-carrier controls), patients with SAD (n = 32) and age-matched controls (n = 11). We found that in the brain, the pattern in ADAD was characterized by an increase in APP b-C-terminal fragment (b-CTF) levels despite no changes in BACE protein levels or activity. In contrast, the pattern in SAD in the brain was mainly characterized by an increase in BACE levels and activity, with less APP b-CTF accumulation than ADAD. In the CSF, no differences were found between groups in BACE activity or expression or sAPPb levels. Taken together, these data suggest that the physiopathological events underlying the chronic Ab production/clearance imbalance in SAD and ADAD are different. These differences should be considered in the design of intervention trials in AD.

Alzheimer's & Dementia, 2014
Background: In this descriptive study of a case series a comparison was made of neuropathological... more Background: In this descriptive study of a case series a comparison was made of neuropathological, neuropsychological and imaging characteristics from two groups of patients with Alzheimer's Disease (AD). One group with sporadic AD (SAD) and another group with familial AD (FAD). Methods: For that, 460 deparaffinized slides from brain tissue were obtained, together with clinical and imaging registries from the Brain Bank of the Neurosciences group of the University of Antioquia. Results: In the neuropathological comparison it was observed that SAD presents more but smaller A b deposits in temporal and occipital cortex compared with FAD. Also, SAD shows correlation between disease duration and neurofibril pathology in temporal cortex. FAD cases present larger deposits in frontal, temporal, parietal and cerebellar areas; together with higher A b immunosignal in the cerebellum. Regarding hyperphosphorylated Tau (pTau) quantification, FAD presents with higher levels in frontal, parietal, occipital and cerebellar areas. Also, It was observed correlations between brain weight, disease duration and pTau in temporal cortex in FAD. In the neuropsychological comparison there were significant differences in total scores for memory, particularly in immediate and long term recovery in a word list task. Imaging comparison showed no differences in cortical atrophy, hippocampal atrophy, fimbriosubicular distance and interuncal distance. Conclusions:

ABSTRACT Normal 0 21 false false false ES X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Defin... more ABSTRACT Normal 0 21 false false false ES X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:&quot;Tabla normal&quot;; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:&quot;&quot;; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:&quot;Times New Roman&quot;; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} Parkinson´s is a common disease (PD) caused by degeneration of dopaminergic neurons in the substantia nigra and other brain areas. Several genes and mutations have been mplicated in its pathogenesis, the latter have been identified mainly in the PARK2 gene. We report the evaluation of this gene and of its flanking region in a large family from the southwestern part of Colombia. The parents are first cousins and four out of their ten children were affected at juvenile age. Molecular evaluation included typing of microsatellites (SSTRs) and direct sequencing of the exons of the gene. Our findings showed the presence, in a homozygous manner, of the mutation c.255delA, at exon 2 of PARK2. In addition, it was possible to identify a haplotype carried by both parents, and present in a homozygous manner in the affected children. A high rate of recombinants was observed in the analysed chromosomal region. Mutation c.255delA in PARK2 had been previously reported in families from both France and Spain. Our findings reconfirm the role of the PARK2 gene in the etiology of Parkinson´s disease, in particular of its juvenile form. Furthermore, taking into account that the identified mutation had been previously found in European populations, it is likely that it came into Colombia from that continent. Alternatively, this mutation might have occurred in a recurrent manner in a close ancestor of the studied family. In order to verify both possibilities it would be necessary to test flanking markers of the mutation in both European and Colombian chromosomes carrying it. Such markers could be either STRs, as reported in this study, or SNPs. La enfermedad de Parkinson (EP) es común y se debe a degeneración de las neuronas dopaminérgicas en la sustancia nigra y en otras áreas del cerebro. Varios genes y mutaciones han sido implicados en ella y la mayoría de estas últimas han sido identificadas en el gen PARK2. Reportamos la evaluación de este gen PARK2 y de su región flanqueante en una gran familia de origen caucano, al suroccidente de Colombia. Los padres son primos hermanos y cuatro de sus diez hijos resultaron afectados en edad juvenil. La evaluación molecular incluyó tipificación de microsatélites (STR) y la secuencia directa de los exones del gen. Nuestros hallazgos evidenciaron la presencia en condición homocigota de la mutación c.255delA, en el exón 2 de PARK2. Además, se pudo identificar un haplotipo portado por ambos padres y presente en condición homocigota en los hijos afectados. Del mismo modo se observó una alta tasa de recombinantes en la extensión de la región cromosómica analizada. La mutación c.255delA en PARK2 ya había sido reportada previamente en familias tanto de Francia como de España. Nuestros resultados reconfirman la participación del gen PARK2 en la etiología de la enfermedad de Parkinson, en particular de la forma juvenil. Además, considerando que la mutación identificada en la familia que presentamos ya había sido previamente encontrada en poblaciones europeas, es probable que haya llegado a Colombia desde allí. Alternativamente, esta mutación pudo ocurrir de manera recurrente en un ancestro más cercano de la familia estudiada; para verificar ambas posibilidades sería necesario evaluar marcadores flanqueantes de la mutación, en los cromosomas europeos y colombianos portadores de la mutación. Tales marcadores pueden ser STR (como se reporta en este estudio) o alternativamente, SNP.

-INTRODUCTION.
(1) Recent evidence shows that familial Alzheimer´s disease (AD)-associated pr... more -INTRODUCTION.
(1) Recent evidence shows that familial Alzheimer´s disease (AD)-associated presenilin-1 mutations alters calcium homeostasis in cellular models (http://www.ncbi.nlm.nih.gov/pubmed/22842534) and in fAD patients (Sepulveda-Falla, 2014), leading to neurodegeneration.
(2) Previous computer simulations have suggested that in AD there are changes in the waveform of [Ca]i (increase in amplitude and speed) and this also occurs in deep sleep (Gomez 2003a,b).
(3) In vitro experiments suggest that Ca-Channels have a frequency dependent behavior (Ricoy and Frerking 2014). (4) EEG-triggered TMS/TES (ETT) can amplify (or reduce) the amplitude of Calcium signaling (Gomez-Molina, SfN 2014). Here, we study the biophysical basis of this stimulation.
-METHODS.
Math-computer models.
-THEORETICAL RESULTS.
ETT can modify the amplitude and apparent speed of electrodiffusion of Ca2+ in a columnar structure. Fig. 1
-DISCUSSION.
(1) If AD patients show increases in Ca2+-amplitude during wakefulness, should we reduce this amplitude during deep sleep or increase it?
(2) Unpredictable effects of electrodiffusion of [Ca2+]o and effects on astrocytes should also be analyzed.
(3) Experimental work is also required.
-CONCLUSIONS.
(1) Using ETT we can increase the Ca2+-amplitude and speed in macrocolumns with opposite local states to global EEG. This might improve function.
(2) If local and global sleep present similar dynamics then reductions in amplitude can be expected during wakefulness after stimulation during sleep.
(3) Weak and friendly stimulation is needed to avoid damage of delicate macromolecular nets around Ca-channels.
(4) Presenilin mutations effect on Ca2+ signaling is characterized by increased intracellular levels mostly surrounding the ER, eventually affecting synaptic activity. This effect could result in excitotoxicity.
Hence, alternatively, it could be desirable to reduce Ca2+ waveform amplitude by TES/TME stimulation in order to compensate ER Ca2+ leakage in neurons.
DOI: 10.13140/RG.2.1.3568.8403 October 2015 Abstract, Society for Neuroscience, www.sfn.org, Meeting-2015 (Text and Figure), Poster, Notes, Abreviations. Pictures.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=f764a1d5-9d4a-4eef-b8db-5ac9ba1bb047&cKey=7b9b1681-f087-4df9-838b-7d2c2bc5cfea&mKey=d0ff4555-8574-4fbb-b9d4-04eec8ba0c84
Program#/Poster#: 93.11/BB36
Location: Hall A
Presentation time: Saturday, Oct 17, 2015, 1:00 PM - 5:00 PM
Presenter at Poster: Sat, Oct. 17, 2015, 3:00 PM - 4:00 PM
Topic: ++G.06.a. Cellular models
Authors:
*Juan Fernando GOMEZ-MOLINA (1),
Ulises M. RICOY (3),
Jaime VELEZ -M.D. (2),
Diego SEPULVEDA-FALLA (4).
(1) International Group of Neuroscience (IGN), Cra 64c #48-94 (603) Medellin, Colombia. Email [email protected]
(2) International Group of Neuroscience (IGN) .US-Member New York, NY.
(3) Department of Biology, Northern New Mexico College
921 N. Paseo de Oñate Española, NM 87532
(4) Inst. of Neuropathology-, Univ. Med. Ctr. Hamburg-Eppendorf and Neurosci. Group of Antioquia, Fac. of Medicine, Univ. of Antioquia, Medellin, Hamburg, Germany
Keyword (s):
TRANSCRANIAL MAGNETIC STIMULATION
LOCAL SLEEP
CALCIUM
Support: International Group of Neuroscience (IGN, Independent, Multi-institutional Support). For ethical, peaceful, non-commercial and responsible applications of Neuroscience (Grant Philosophy: ¨Science for exploration, not for domination”).

Even though cognitive impairment in brain vascular disease has been widely described, there is no... more Even though cognitive impairment in brain vascular disease has been widely described, there is not much known about specific neuropsychological profiles in affected families suffering from hereditary vascular dementia CADASIL. In Colombia we have reported for the first time two large kindreds suffering from CADASIL in the Antioquia region (Colombia). Those families carry mutations R1031C and C455R in notch 3 gene, respectively. In this study, we have develop a comparative analysis between 16 affected carriers of R1031C (family A) and 7 affected carriers of mutation C455R (family B). This includes a description of cognitive performance in these two groups applying specific protocols evaluating several cognitive functions, depression and everyday functionality. Analysis showed differences in age of onset, evolution time, dementia diagnosis and degree of leukoencephalopaty between R1031C and C455R carriers. Statistically significant differences were found in tests evaluating multiple cognitive domains with higher prevalence of cognitive impairment and dementia in R1031C carriers (p<0.05). There were not statistically significant differences in tests evaluating sustained attention, abstract reasoning, semantical and phonological fluence, reading, arithmetic, executive functions, depression scales and functional scales.
Iatreia, 2010
Dehydroepiandrosterone sulfate (DHEA-S) is a neurosteroid that has effects such as neuromodulator... more Dehydroepiandrosterone sulfate (DHEA-S) is a neurosteroid that has effects such as neuromodulator of synaptic transmission and neuroprotection. The specific signaling pathways for these effects are not elucidated yet. Given that, some neurosteroids act through the activation of ...

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006
We previously identified in two families with early onset Parkinson&amp;amp;amp;amp;amp;amp;a... more We previously identified in two families with early onset Parkinson&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s Disease (PD) from the isolated population of Antioquia (Colombia), a parkin Cys212Tyr substitution caused by a G736A mutation. This mutation was subsequently observed in a Spanish family, suggesting that it could have been taken to Antioquia by Spanish immigrants. Here we screened for the G736A mutation in additional Antioquian early onset PD cases and used haplotype analysis to investigate the relationship between Spanish and Antioquian G736A chromosomes. We confirmed the occurrence of an extensive founder effect in Antioquia. Thirteen individuals (10 homozygotes) from seven nuclear families were identified with the G736A mutation. Genealogical investigations demonstrated the existence of shared ancestors between six of these families four to five generations ago and no evidence of Spanish ancestry during this period. A second parkin mutation (a duplication of exon 3), was detected in the three G736A heterozygote carriers. Haplotype data exclude a recent common ancestry between the Spanish and Antioquian patients studied here and is consistent with the introduction of the G736A mutation in Antioquia during early colonial times (about 16 generations ago).
Uploads
Papers by Diego Sepulveda-falla
(1) Recent evidence shows that familial Alzheimer´s disease (AD)-associated presenilin-1 mutations alters calcium homeostasis in cellular models (http://www.ncbi.nlm.nih.gov/pubmed/22842534) and in fAD patients (Sepulveda-Falla, 2014), leading to neurodegeneration.
(2) Previous computer simulations have suggested that in AD there are changes in the waveform of [Ca]i (increase in amplitude and speed) and this also occurs in deep sleep (Gomez 2003a,b).
(3) In vitro experiments suggest that Ca-Channels have a frequency dependent behavior (Ricoy and Frerking 2014). (4) EEG-triggered TMS/TES (ETT) can amplify (or reduce) the amplitude of Calcium signaling (Gomez-Molina, SfN 2014). Here, we study the biophysical basis of this stimulation.
-METHODS.
Math-computer models.
-THEORETICAL RESULTS.
ETT can modify the amplitude and apparent speed of electrodiffusion of Ca2+ in a columnar structure. Fig. 1
-DISCUSSION.
(1) If AD patients show increases in Ca2+-amplitude during wakefulness, should we reduce this amplitude during deep sleep or increase it?
(2) Unpredictable effects of electrodiffusion of [Ca2+]o and effects on astrocytes should also be analyzed.
(3) Experimental work is also required.
-CONCLUSIONS.
(1) Using ETT we can increase the Ca2+-amplitude and speed in macrocolumns with opposite local states to global EEG. This might improve function.
(2) If local and global sleep present similar dynamics then reductions in amplitude can be expected during wakefulness after stimulation during sleep.
(3) Weak and friendly stimulation is needed to avoid damage of delicate macromolecular nets around Ca-channels.
(4) Presenilin mutations effect on Ca2+ signaling is characterized by increased intracellular levels mostly surrounding the ER, eventually affecting synaptic activity. This effect could result in excitotoxicity.
Hence, alternatively, it could be desirable to reduce Ca2+ waveform amplitude by TES/TME stimulation in order to compensate ER Ca2+ leakage in neurons.
DOI: 10.13140/RG.2.1.3568.8403 October 2015 Abstract, Society for Neuroscience, www.sfn.org, Meeting-2015 (Text and Figure), Poster, Notes, Abreviations. Pictures.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=f764a1d5-9d4a-4eef-b8db-5ac9ba1bb047&cKey=7b9b1681-f087-4df9-838b-7d2c2bc5cfea&mKey=d0ff4555-8574-4fbb-b9d4-04eec8ba0c84
Program#/Poster#: 93.11/BB36
Location: Hall A
Presentation time: Saturday, Oct 17, 2015, 1:00 PM - 5:00 PM
Presenter at Poster: Sat, Oct. 17, 2015, 3:00 PM - 4:00 PM
Topic: ++G.06.a. Cellular models
Authors:
*Juan Fernando GOMEZ-MOLINA (1),
Ulises M. RICOY (3),
Jaime VELEZ -M.D. (2),
Diego SEPULVEDA-FALLA (4).
(1) International Group of Neuroscience (IGN), Cra 64c #48-94 (603) Medellin, Colombia. Email [email protected]
(2) International Group of Neuroscience (IGN) .US-Member New York, NY.
(3) Department of Biology, Northern New Mexico College
921 N. Paseo de Oñate Española, NM 87532
(4) Inst. of Neuropathology-, Univ. Med. Ctr. Hamburg-Eppendorf and Neurosci. Group of Antioquia, Fac. of Medicine, Univ. of Antioquia, Medellin, Hamburg, Germany
Keyword (s):
TRANSCRANIAL MAGNETIC STIMULATION
LOCAL SLEEP
CALCIUM
Support: International Group of Neuroscience (IGN, Independent, Multi-institutional Support). For ethical, peaceful, non-commercial and responsible applications of Neuroscience (Grant Philosophy: ¨Science for exploration, not for domination”).
(1) Recent evidence shows that familial Alzheimer´s disease (AD)-associated presenilin-1 mutations alters calcium homeostasis in cellular models (http://www.ncbi.nlm.nih.gov/pubmed/22842534) and in fAD patients (Sepulveda-Falla, 2014), leading to neurodegeneration.
(2) Previous computer simulations have suggested that in AD there are changes in the waveform of [Ca]i (increase in amplitude and speed) and this also occurs in deep sleep (Gomez 2003a,b).
(3) In vitro experiments suggest that Ca-Channels have a frequency dependent behavior (Ricoy and Frerking 2014). (4) EEG-triggered TMS/TES (ETT) can amplify (or reduce) the amplitude of Calcium signaling (Gomez-Molina, SfN 2014). Here, we study the biophysical basis of this stimulation.
-METHODS.
Math-computer models.
-THEORETICAL RESULTS.
ETT can modify the amplitude and apparent speed of electrodiffusion of Ca2+ in a columnar structure. Fig. 1
-DISCUSSION.
(1) If AD patients show increases in Ca2+-amplitude during wakefulness, should we reduce this amplitude during deep sleep or increase it?
(2) Unpredictable effects of electrodiffusion of [Ca2+]o and effects on astrocytes should also be analyzed.
(3) Experimental work is also required.
-CONCLUSIONS.
(1) Using ETT we can increase the Ca2+-amplitude and speed in macrocolumns with opposite local states to global EEG. This might improve function.
(2) If local and global sleep present similar dynamics then reductions in amplitude can be expected during wakefulness after stimulation during sleep.
(3) Weak and friendly stimulation is needed to avoid damage of delicate macromolecular nets around Ca-channels.
(4) Presenilin mutations effect on Ca2+ signaling is characterized by increased intracellular levels mostly surrounding the ER, eventually affecting synaptic activity. This effect could result in excitotoxicity.
Hence, alternatively, it could be desirable to reduce Ca2+ waveform amplitude by TES/TME stimulation in order to compensate ER Ca2+ leakage in neurons.
DOI: 10.13140/RG.2.1.3568.8403 October 2015 Abstract, Society for Neuroscience, www.sfn.org, Meeting-2015 (Text and Figure), Poster, Notes, Abreviations. Pictures.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=f764a1d5-9d4a-4eef-b8db-5ac9ba1bb047&cKey=7b9b1681-f087-4df9-838b-7d2c2bc5cfea&mKey=d0ff4555-8574-4fbb-b9d4-04eec8ba0c84
Program#/Poster#: 93.11/BB36
Location: Hall A
Presentation time: Saturday, Oct 17, 2015, 1:00 PM - 5:00 PM
Presenter at Poster: Sat, Oct. 17, 2015, 3:00 PM - 4:00 PM
Topic: ++G.06.a. Cellular models
Authors:
*Juan Fernando GOMEZ-MOLINA (1),
Ulises M. RICOY (3),
Jaime VELEZ -M.D. (2),
Diego SEPULVEDA-FALLA (4).
(1) International Group of Neuroscience (IGN), Cra 64c #48-94 (603) Medellin, Colombia. Email [email protected]
(2) International Group of Neuroscience (IGN) .US-Member New York, NY.
(3) Department of Biology, Northern New Mexico College
921 N. Paseo de Oñate Española, NM 87532
(4) Inst. of Neuropathology-, Univ. Med. Ctr. Hamburg-Eppendorf and Neurosci. Group of Antioquia, Fac. of Medicine, Univ. of Antioquia, Medellin, Hamburg, Germany
Keyword (s):
TRANSCRANIAL MAGNETIC STIMULATION
LOCAL SLEEP
CALCIUM
Support: International Group of Neuroscience (IGN, Independent, Multi-institutional Support). For ethical, peaceful, non-commercial and responsible applications of Neuroscience (Grant Philosophy: ¨Science for exploration, not for domination”).